Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven DecisionsBusiness Wire • 02/12/24
Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024Business Wire • 02/02/24
Compared to Estimates, Revvity (RVTY) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/01/24
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023Business Wire • 02/01/24
Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of DirectorsBusiness Wire • 01/25/24
Revvity, Inc. (RVTY) CEO Prahlad Singh presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/09/24
Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial PerformanceBusiness Wire • 01/09/24
Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCIDBusiness Wire • 11/27/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revvity, Inc. - RVTYPRNewsWire • 11/03/23
Revvity tumbles on 3Q earnings miss; revised guidance in “increasingly challenging” environmentProactive Investors • 10/30/23
Compared to Estimates, Revvity (RVTY) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/30/23
Revvity's stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlookMarket Watch • 10/30/23